efavirenz has been researched along with Atherogenesis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| An, W; Hu, J; Hu, W; Li, Q; Shen, X; Yang, M | 1 |
| Amogne, W; Assefa, G; Caulk, AW; Getenet, H; Gleason, RL; Parker, I; Seifu, D; Vidakovic, B | 1 |
| Abebe, W; Amogne, W; Caulk, AW; Eckard, AR; Gleason, RL; Rosebush, JC; Schwartz, MH; Seifu, D; Shapiro, AM | 1 |
3 other study(ies) available for efavirenz and Atherogenesis
| Article | Year |
|---|---|
Relationships of Liver X Receptor Antagonists and Atherosclerosis in Drinking Water from Six Chinese Major Cities.
Topics: Atherosclerosis; China; Cholesterol; Cities; Drinking Water; East Asian People; Humans; Liver X Receptors | 2023 |
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
Topics: Adult; Alkynes; Anti-HIV Agents; Atherosclerosis; Benzoxazines; Biomarkers; Blood Pressure; C-Reactive Protein; Carotid Intima-Media Thickness; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Ethiopia; Female; Heart Rate; HIV Infections; HIV-1; Humans; Lipodystrophy; Lopinavir; Male; Middle Aged; Nevirapine; Pulse Wave Analysis; Ritonavir; Triglycerides | 2015 |
Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atherosclerosis; Benzoxazines; Biomarkers; Carotid Intima-Media Thickness; Child; Cyclopropanes; Ethiopia; Female; HIV Infections; Humans; Lipids; Lopinavir; Male; Middle Aged; Pulse Wave Analysis; Ritonavir; Young Adult | 2016 |